

AI & BIG DATA

LIFE SCIENCE*

EXPERIENCES FROM
NOVO NORDISK * ABZU * RAIT * IQVIA
NOVARTIS * DAWN HEALTH * CEREBRIU
INSIFE

relevent*

IN COOPERATION WITH

MEDWATCH **itwatch** **Bech·Bruun**

PARTNER

**DANSK
ERHVERV**



Danish
Life Science
Cluster

SPONSOR

KPMG

IN COOPERATION WITH

PARTNER

SPONSOR

MEDWATCH

MedWatch reports on the pharmaceutical and medtech industry in Denmark, which are important areas beyond the domestic commercial sector and play a vital role for public health and society in general. MedWatch delivers independent, critical and fair journalism and focuses on core substance.

ITwatch

ITWatch closely follows Danish IT and telecommunication players, focusing on the businesses behind the products. We cover strategy, management, results, competition, policy, orders, acquisitions, innovation, careers, job moves and much more. ITWatch delivers independent, critical and fair journalism about the large, leading firms – but also the sub-canopy of small and medium-sized businesses that form the backbone of Denmark's private sector and general society.

Bech·Bruun

Bech-Bruun is a market-oriented law firm offering a wide range of specialist advisory services to large sections of the Danish corporate and public sectors as well as global enterprises. Counting more than 500 experienced and highly specialised employees, of which 69 are partners, we are one of Denmark's leading full-service law firms.

We have the size and specialist skills to field the best legal team at any time. As our client you can expect valuable and value-adding advisory services. You gain access to a wide range of legal specialist skills. But just as importantly, you will find in-depth understanding of your business reality.

**DANSK
ERHVERV****KPMG**

KPMG is a global network of professional services firms providing Audit, Tax and Advisory services. We operate in 153 countries and have 207,000 people working in member firms around the world. We work closely with a broad range of clients, such as business corporations, governments and public sector agencies and not-for-profit organisations. We support them in mitigating risks and exploiting business opportunities. KPMG in Denmark is the fastest growing professional services firm in Denmark, with a revenue of DKK close to 700m in FY18. More than 600 employees and partners ignite potential in clients, delivering value to them with a combination of deep local insight and strong global perspectives.

LIST OF SPEAKERS

Moderatorer:

Partner
Martin Dræbye Gantzhorn
Bech-Bruun

- * Partner, NewTech
Michael Birkebæk Jensen
KPMG
- * Business Development Manager
Daniel Thulstrup
*Strategy & Business Development
Novo Nordisk A/S*
- * Bioinformatician
Lykke Pedersen
Abzu
- * Bioinformatician
Samuel Demharter
Abzu
- * Senior Director Digital Transformation
Søren Klim
Novo Nordisk A/S
- * Manager, Biostatistics Aalborg 1
Steffen Nørgaard Vangsgaard
Novo Nordisk A/S
- * EMEA Lead, Predictive Analytics and Genomics
Ashley Pitcher
IQVIA
- * Founder & CEO
Daniel Gewecke Daugaard
Dawn Health

- * Project Manager
Charlotte Trap-Kinberg
RAIT (Radiological Artificial Intelligence Testcenter)
- * CEO
Robert Lauritzen
Cerebriu
- * Associate Director in Data Science
Kostas Sechidis
Novartis
- * CEO
Martin Holm-Petersen
Insife
- * Vice President Digital Health
Søren Smed Østergaard
Novo Nordisk A/S

PROGRAM

09:00-09:05 WELCOME

Partner **Martin Dræbye Gantzhorn**, *Bech-Bruun*

09:05-09:35 RETHINK PHYSICAL PROCESSES

In this session we will hear about how the New-Practice methodology and cutting edge technology can be used to rethink physical processes with a special focus on quality control and warehousing

Partner NewTech **Michael Birkebæk Jensen**, *KPMG*

09:35-10:05 RETHINKING RAW MATERIAL TRACEABILITY THROUGH NEWPRACTICE AT NOVO NORDISK

Novo Nordisk annually receives over 500.000 units of raw materials for their insulin production. To ensure that the highest standards of safety and quality Novo Nordisk has developed their own printed labels that they manually apply to each of these units. While important, the process of printing, applying and scanning these labels is prone to errors and inefficiency. Through a pilot project Novo Nordisk has hired KPMG NewTech to assist in rethinking this process with new technology and new practices at the centre

Business Development Manager,
Daniel Thulstrup,
Strategy & Business Development,
Novo Nordisk A/S

10:05-10:20 NETWORKING BREAK**10:20-11:00 ACCELERATING SCIENTIFIC DISCOVERIES WITH EXPLAINABLE AI**

Data has the potential to lead to knowledge. But how do we best extract knowledge from data? Explainable AI holds the promise of delivering predictions that are understandable to a human mind. In this talk we present how we use xAI to

reveal insights regarding drug discovery and biomarker identification. We show what it means to have simple non-linear models that reveal otherwise hidden relationships in your data. Tune in to see how Abzu is pushing the boundaries of its unique technology to bring us closer to the promise of precision medicine.

Bioinformatician **Lykke Pedersen**, *Abzu*

Bioinformatician **Samuel Demharter**, *Abzu*

11:00-11:35 FACT – FAST ACCESS TO CLINICAL TRIAL INSIGHTS

Novo Nordisk presents a new custom-built tool for effective knowledge sharing on clinical trial results across the organization. The tool is called FACT (Fast Access to Clinical Trial insights) and uses both Natural Language Processing (NLP) algorithms and OCR technologies to make the clinical trials results searchable.

FACT is a web application with a classic search engine interface with the possibility to create advanced searches with a range of different filters. This creates a completely new way of accessing data.

If you are interested in activation of unstructured data across clinical trials, NLP, relevance scoring and increasing access to data across your organization, then Novo Nordisk FACT is an interesting initiative for you to follow

Senior Director, Digital Transformation
Søren Klim, *Novo Nordisk A/S*

Manager, Biostatistics Aalborg 1
Steffen Nørgaard Vangsgaard, *Novo Nordisk A/S*

11:35-11:45 SHORT BREAK**11:45-12:15 USE OF REAL WORLD DATA WITH AI ACROSS THE PRODUCT LIFE CYCLE**

We are in the midst of an explosion of health-care data. Find out how life science companies are using artificial intelligence with real world patient data to better understand diseases, patients and outcomes, and help get the right treatments to the right patients at the right time.

Predictive analytics and genomics, EMEA Lead
Ashley Pitcher, *IQVIA*

12:15-13:15 LUNCH AND TIME TO NETWORK**13:15-13:50 CODE TO SAVE LIVES**

Founder & CEO **Daniel Gewecke Daugaard**,
Dawn Health

13:50-14:20 RAIT

Project Manager **Charlotte Trap-Kinberg**, *RAIT*
(Radiological Artificial Intelligence Testcenter)

14:20-14:35 NETWORKING BREAK**14:35-15:05 INFUSING CLINICAL INTELLIGENCE AT THE POINT OF IMAGING**

Diagnostic imaging demand is growing at an alarming and accelerating rate. Cerebriu automates radiology workflows infusing clinical intelligence at the point of imaging. This session discusses why moving from post-processing to real-time analysis can improve workflow efficiency and manage the bottlenecks, but also why this is relevant not only in clinical practice, but also in clinical research.

CEO **Robert Lauritzen**, *Cerebriu*

PROGRAM

15.05-15:40 ARTIFICIAL INTELLIGENCE FOR DRUG SAFETY / SIDE EFFECTS PROCESSING – WHAT IS POSSIBLE TODAY?

Drug side effect reporting is a massive undertaking for Pharmaceutical companies and Regulatory agencies. Lately, with global COVID-19 vaccine programs, further impact on side effect volumes have been experienced. Using advanced automa-

tion such as artificial intelligence is a promising way to cope more efficiently with work-loads, but here a number of challenges are to be tackled. In this session, we will go through learnings from the recently completed, drug safety-focused “AI Data Analyzer” public-private (Innoboster) initiative as well as the ongoing automation work with a Regulatory agency, with the aim of suggesting how and where to get the most value of machine-derived data in the actual processing of side effect reports.

CEO **Martin Holm-Petersen**, *Insife*

15:40-15:50 NETWORKING BREAK**15:50-16:25 QUANTIFYING UNCERTAINTY ON MACHINE LEARNING BASED PREDICTIVE BIOMARKER DISCOVERY**

One of the key challenges of personalized medicine is to identify which patients will respond positively to a given treatment. The area of subgroup identification focuses on this challenge, that is, identifying groups of patients that experience desirable characteristics, such as an enhanced treatment effect. A crucial first step towards the subgroup identification is to identify the baseline variables (eg, biomarkers) that influence the treatment effect, which are known as predictive biomarkers. Many machine learning algorithms for subgroup discovery algorithms return importance scores that capture the variables’ predictive strength. However, a major limitation of these scores is that they do not

answer the core question: “Which variables are actually predictive?” In this talk we answer this question by using the knockoff framework.

Associate Director in Data Science
Kostas Sechidis, *Novartis*

16.25-16.55 THE TRANSFORMATIVE POTENTIAL OF LARGE SCALE MEDICATION USAGE DATA ON CHRONIC CARE OUTCOMES

In this session, taking point of departure on a real life example from a Swedish study in diabetes, we outline how the passive collection and usage of medication usage data, correlated to other relevant data sets could have the potential to change care delivery, by facilitating better, more productive conversations at point of care as well as create the foundation for digital therapeutic solutions that can set the bar higher for realised health outcomes to the benefit of people living with chronic diseases and society.

Vice President Digital Health
Søren Smed Østergaard, *Novo Nordisk A/S*

16.55-17.00 CLOSING REMARKS

Partner **Martin Dræbye Gantzhorn**, *Bech-Bruun*

PRISER & PRAKTIK

REGISTRATION FEE

REGISTRATION	Early bird by 5 November 2021	Regular fee after 5 November 2021
	DKK 5.495,- (+ VAT)	DKK 5.995,- (+ VAT)

Registration fee includes conference delegate material, refreshments and lunch. Accommodation is **not** included.

3-at-2 discount - 3 delegates from the same company, that register at the same time, pay the price of 2

Members of The Danish Chamber of Commerce get a member discount – please inform us about your membership when registering.

Discounts can not be combined.

WHERE

Charlottehaven, Hjørtinggade 12C, 2100 København Ø, telefon +45 3527 1500

WHEN

Thursday 24 November

REGISTRATION

Registration at info@relevent.dk – please contact +45 2830 5445 or +45 4195 1429 with any questions.

Cancellations must be given in writing to info@relevent.dk and will be subject to a fee.

Cancellation fee before 10 NOVEMBER 2021 - 10% of registration fee.

Cancellation fee before 17 NOVEMBER 2021 - 50% of registration fee.

Cancellation fee from 19 NOVEMBER 2021 – no refund, thus 100% of registration fee.

To avoid cancellation fees – you may transfer your registration to a colleague.

Please inform Relevent prior to the conference in writing to info@relevent.dk